Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.13
(
0.61%
)
Bitcoin
77,115.07
(
-0.38%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 109449

Wednesday, 11/24/2010 12:54:12 PM

Wednesday, November 24, 2010 12:54:12 PM

Post# of 257580

Last month Roche said they are moving forward with an INFORM-SVR study (RG7227 with ritonavir boosting), which should start Q1/11. What's the point of Roche mentioning INFORM-SVR if in fact INFORM is completely dead?

Since then, Roche announced a major restructuring, which includes pruning some clinical programs. RG7227/INFORM is probably one of the programs being pruned, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today